Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy with varying application times for actinic keratosis on hands
2014-002756-11Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Aug 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Lesion clearance rate at 3 months. Started Aug 2014; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2014-002756-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002756-11.